share_log

Goldman Sachs Initiates Coverage On Immunovant With Buy Rating, Announces Price Target of $50

Moomoo 24/7 ·  Mar 13 08:38

Goldman Sachs analyst Corinne Johnson initiates coverage on Immunovant (NASDAQ:IMVT) with a Buy rating and announces Price Target of $50.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment